Vascular alterations during the development and progression of experimental heart failure

M J Crespo1

  • 1Department of Pharmacology, University of Puerto Rico-School of Medicine, San Juan 00936-5067.

Insights

Congestive heart failure (HF) progression is linked to vascular changes. Increased vascular response to norepinephrine (NE) and hyperreactivity to angiotensin II (Ang II) in young hamsters predict HF severity.

Area of Science:

  • Cardiovascular Science
  • Vascular Biology
  • Heart Failure Pathogenesis

Background:

  • Congestive heart failure (HF) involves complex systemic and vascular changes.
  • The precise mechanisms driving HF onset and progression remain unclear.
  • Understanding the temporal development of vascular alterations is crucial for HF research.

Purpose of the Study:

  • To investigate the temporal evolution of vascular alterations in heart failure (HF).
  • To assess the contribution of vascular reactivity and angiotensin-converting enzyme (ACE) activity to HF pathogenesis.
  • To utilize the Syrian cardiomyopathic hamster (SCH) model for studying HF development.

Main Methods:

  • Assessed vascular reactivity to angiotensin II (Ang II) and norepinephrine (NE) in SCH hamsters at 2, 6, and 11 months.
  • Measured circulating and local angiotensin-converting enzyme (ACE) activity in plasma and heart tissue.
  • Compared vascular responses and ACE activity in SCH hamsters with age-matched normal controls.

Main Results:

  • SCH hamsters exhibited enhanced aortic ring contractile response to Ang II, increasing with age.
  • Norepinephrine (NE) induced a greater maximal contraction in SCH hamsters compared to controls across ages.
  • Elevated ACE activity was observed in the plasma and heart tissue of older SCH hamsters.

Conclusions:

  • Increased vascular response to NE and Ang II hyperreactivity in young SCH animals are critical factors in HF development.
  • Ang II-induced contractility and ACE activity serve as reliable predictors for HF progression and severity.
  • These findings highlight the role of vascular factors in the pathogenesis of congestive heart failure.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
385
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
352
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
987
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
937
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K